Image Description

INVESTORS
& MEDIA

circle

PRESS RELEASES

  • Webcast Image Webcast
    X Q4 2018 Cytokinetics, Inc. Earnings Conference Call
    Feb 21, 2019 4:30 PM EST

    Q4 2018 Cytokinetics, Inc. Earnings Conference Call
    Feb 21, 2019 4:30 PM EST
Date Title and Summary
Toggle Summary Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure to Continue Without Changes THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, March 20, 2019 (GLOBE NEWSWIRE) -- Amgen (NASDAQ: AMGN), Cytokinetics,
Toggle Summary Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at ACC.19
No Difference in Treatment Effects of Omecamtiv Mecarbil in Patients with Heart Failure Irrespective of Atrial Fibrillation SOUTH SAN FRANCISCO, Calif. , March 18, 2019 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq: CYTK) today announced that additional results from COSMIC-HF ( C hronic O
Toggle Summary Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at ACC.19
SOUTH SAN FRANCISCO, Calif. , March 11, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncrease C ontractility in H eart F ailure), a Phase 2 trial evaluating omecamtiv
Toggle Summary Cytokinetics Announces Presentation of Results From FORTITUDE-ALS at the American Academy of Neurology 71st Annual Meeting
SOUTH SAN FRANCISCO, Calif. , March 07, 2019 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq: CYTK) today announced that results from FORTITUDE-ALS ( F unctional  O utcomes in a  R andomized  T rial of  I nvestigational  T reatment with CK-2127107 to  U nderstand  D ecline in  E ndpoints –
Toggle Summary Cytokinetics Joins Global Initiative To Recognize International Rare Disease Day
SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq: CYTK) today announced that it is standing with the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) to recognize Rare Disease Day®, an
Toggle Summary Cytokinetics Reports Fourth Quarter 2018 Financial Results
Company Provides 2019 Financial Guidance and Expected Milestones Reduced Operating Expenses vs. 2018; Over Two Years of Cash Based on Current Burn Rate Interim Analysis for GALACTIC-HF on Track for 1H 2019 Results from FORTITUDE-ALS Expected in Q2 2019 SOUTH SAN FRANCISCO, Calif. , Feb.
Toggle Summary Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
THOUSAND OAKS, Calif. , SOUTH SAN FRANCISCO, Calif. , and SURESNES, France, Feb. 21, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF ( M ulticenter E xercise T olerance E valuation of O mecamtiv Mecarbil R elated to I
Toggle Summary Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator
Advancement of Second Novel Mechanism Cardiac Sarcomere Activator Reinforces Leadership Position in Muscle Directed Pharmacology SOUTH SAN FRANCISCO, Calif. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first subject has been dosed in a Phase
Toggle Summary Cytokinetics to Announce Fourth Quarter Results on February 21, 2019
SOUTH SAN FRANCISCO, Calif. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report fourth quarter results on February 21, 2019 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics Announces Receipt of FDA Feedback Regarding Reldesemtiv in Patients With SMA
Six Minute Walk Test Acceptable as Primary Efficacy Endpoint for Potential Registration Program SOUTH SAN FRANCISCO, Calif. , Jan. 22, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it has received feedback from the U.S.